The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
And when the long-awaited trial does finally report it will have to be a smash hit.
After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
The company’s off-the-shelf T-cell immunotherapy seems to be improving multile sclerosis disability, but an ongoing phase 2 trial will provide a better test.